TUSTIN, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a
dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality
development and manufacturing services to biotechnology and pharmaceutical companies, today announced that it will report financial
results for the third quarter of fiscal year 2018 ended January 31, 2018 on March 12, 2018 after market close and will
host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Avid's senior management will discuss financial
results for the third quarter and review recent corporate developments.
To listen to the live webcast, or access the archived webcast, please visit: http://ir.avidbio.com/events.cfm.
To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Avid Bioservices
call.
About Avid Bioservices, Inc.
Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and
cGMP manufacturing of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive
range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and
biopharmaceutical industries. With nearly 25 years of experience producing monoclonal antibodies and recombinant proteins in
batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing, purification,
bulk packaging, stability testing and regulatory strategy, submission and support. The company also provides a variety of
process development activities, including cell line development and optimization, cell culture and feed optimization, analytical
methods development and product characterization. www.avidbio.com
Contacts: Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 sdiaz@vidasp.com Tim Brons (Media) Vida Strategic Partners 415-675-7402 tbrons@vidasp.com
